Dyslipidemia in special ethnic populations.
This article reviews racial/ethnic differences in dyslipidemia-prevalence of dyslipidemia, its relation to coronary heart disease (CHD) and stroke mortality rates, response to lipid-lowering agents, and lifestyle modification. Asian Indians, Filipinos, and Hispanics are at higher risk for dyslipidemia, which is consistent with the higher CHD mortality rates in these groups. Statins may have greater efficacy for Asians, but the data are mixed. Lifestyle modifications are recommended. Culturally-tailored prevention and intervention should be provided to the minority populations with elevated risk for dyslipidemia and considerably more research is needed to determine the best approaches to helping specific subgroups.
Palo Alto Medical Foundation Research Institute, Ames Building, 795 El Camino Real, Palo Alto, CA 94301, USA. Electronic address: puj@pamfri.org.
Jia
J
Pu
Palo Alto Medical Foundation Research Institute, Ames Building, 795 El Camino Real, Palo Alto, CA 94301, USA.
Robert
R
Romanelli
Palo Alto Medical Foundation Research Institute, Ames Building, 795 El Camino Real, Palo Alto, CA 94301, USA.
Beinan
B
Zhao
Palo Alto Medical Foundation Research Institute, Ames Building, 795 El Camino Real, Palo Alto, CA 94301, USA.
Kristen M J
KM
Azar
Stanford University School of Medicine, 1265 Welch Road, Stanford, CA 94305, USA.
Katherine G
KG
Hastings
Palo Alto Medical Foundation Research Institute, Ames Building, 795 El Camino Real, Palo Alto, CA 94301, USA.
Vani
V
Nimbal
Kaiser Permanente Center for Health Research, 3800 North Interstate Avenue, Portland, OR 97227, USA.
Stephen P
SP
Fortmann
Stanford University School of Medicine, 1265 Welch Road, Stanford, CA 94305, USA.
Latha P
LP
Palaniappan
D019468:Disease Management; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy / Q000208:ethnology; D005006:Ethnicity; D014943:Global Health; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D015995:Prevalence; D012307:Risk Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids
Dyslipidemia; Lifestyle modification; Mortality; Prevalence; Racial/ethnic differences; Treatment